New combo aims to control lung cancer after first treatment fails

NCT ID NCT06127303

Recruiting now Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tests whether adding a freezing treatment (cryoablation) to an immunotherapy drug (toripalimab) can help control advanced non-small cell lung cancer that has started to grow again after initial treatment. About 54 adults with a specific type of lung cancer will receive the combination. The goal is to see if it can slow down the cancer and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhongshan Hospital, Fudan University
NOT_YET_RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER